Background: Recent studies suggest that myocardial administration of stem cells improves perfusion and function of ischemic myocardium. The present study evaluated the safety and efficacy of simple intracoronary administration of mononuclear autologous bone marrow(BM)cells in patients with ischemic cardiomyopathy without revascularization option. Methods and Results: We enrolled 6 consecutive patients with ischemic cardiomyopathy,who were in New York Heart Association classes III to IV despite optimal medical treatment without revascularization options and who, on dobutamine stress echocardiograph(DSE), were found to have left ventricular ejection fraction< 35% with significant hibernation and ischemia in at least 2 myocardial segments. BM cell suspension was collected, and on the next day, during coronary angiography, mild ischemia was induced by a short balloon inflation in each coronary conduit with a TIMI flow of ≥ 2 followed by slow infusion of up to 50 mL of BM cells suspension to each conduit. At baseline and 4 months follow-up,patients underwent clinical evaluation, Holter monitoring, and DSE. BM infusion was successful in all patients. One patient developed postprocedure hypotension and troponin increase. At 4 months follow-up New York Heart Association class improved from 3.5± 0.5 to 2.3± 1.0, P=.04, and resting ejection fraction improved from 25% ± 7% to 28% ± 8% , P=.055. We observed improvement in resting wall motion score only in the segments with hibernation in baseline DSE(2.3± 0.5 to 2.0± 0.6, P=.03)and improvement in high-dose dobutamine wall motion score, only in segments showing significant ischemia at baseline DSE(2.5± 0.5 to 2.0± 0.6, P=.001). There were no clinical arrhythmias or increased arrhythmia burden by Holter monitoring. Conclusions: In patients with severe symptomatic ischemic cardiomyopathy, mild induction of ischemia followed by intracoronary infusion of unmanipulated autologous BM is feasible and safe and may improve hibernation and ischemia. Background: Recent studies suggest that myocardial administration of stem cells improves perfusion and function of ischemic myocardium. The present study evaluating the safety and efficacy of simple intracoronary administration of mononuclear autologous bone marrow (BM) cells in patients with ischemic cardiomyopathy without revascularization option. Methods and Results: We enrolled 6 consecutive patients with ischemic cardiomyopathy, who were in New York Heart Association classes III to IV despite optimal medical treatment without revascularization options and who, on dobutamine stress echocardiograph (DSE), were found to have left ventricular ejection fraction < 35% with significant hibernation and ischemia in at least 2 myocardial segments. BM cell suspension was collected, and on the next day, during coronary angiography, mild ischemia was induced by a balloon inflation in each coronary conduit with a TIMI flow of ≥ 2 followed by slow infusion of up to 50 mL of BM cells suspension At baseline and 4 months follow-up, patients underwent clinical evaluation, Holter monitoring, and DSE. One patient developed postprocedure hypotension and troponin increase. At 4 months’follow-up New York Heart Association class improved from 3.5 ± 0.5 to 2.3 ± 1.0, P = .04, and resting ejection fraction improved from 25% ± 7% to 28% ± 8%, P = .055. We observed improvement in resting wall motion score only in the segments with hibernation in baseline DSE (2.3 ± 0.5 to 2.0 ± 0.6, P = .03) and improvement in high-dose dobutamine wall motion score, only in segments showed significant ischemia at baseline DSE (2.5 ± 0.5 to 2.0 ± 0.6, P = .001). There were no clinical arrhythmias or increased arrhythmia burden by Holter monitoring. Conclusions: In patients with severe symptomatic ischemic cardiomyopathy, mild induction of ischemia followed by intracoronary infusion of unmanipulated autologous BM is feasible and safe and may improv e hibernationand ischemia.